Colorado Rocky Mountain Health Plans Discogenic Pain Coverage

Coverage Criteria and Evidence Summary

inv-01: Not medically necessary / Unproven interventions

The policy states the following procedures are unproven and not medically necessary due to insufficient evidence of efficacy:

Unproven / Not Medically Necessary Procedures: Annular closure devices (ACDs); Percutaneous injection of allogeneic cellular/tissue-based products; Thermal intradiscal procedures (TIPs)

Explicitly listed as unproven/not medically necessary in Coverage Rationale.

inv-02: Annular Closure Devices (ACDs)

ACD implantation — evidence summary and patient selection factors

ACD evidence summary: Randomized trials and systematic reviews report reduced symptomatic reherniation and reoperation rates with bone‑anchored annular closure devices (e.g., Barricaid) in selected patients with large post‑discectomy annular defects, but overall evidence quality is low with limitations including small or overlapping study cohorts, industry sponsorship, risk of bias, and limited long‑term follow-up.

Safety concerns observed include implantation difficulties, mesh detachment or migration, and vertebral endplate changes; device labeling and trial inclusion required assessment of annular defect size, adequate disc height, and non‑osteoporotic BMD.

ACD patient selection factors: Trials enrolled patients with large annular defects typically ≥ 6 mm in width after single‑level lumbar discectomy (commonly L4–S1); positive selection factors included preserved disc height and acceptable bone mineral density. Shared decision‑making regarding reoperation risk influenced outcomes in trials.Annular defect size typically ≥ 6 mm (trial inclusion; device labeling: 4–6 mm tall and 6–10 mm wide)

FDA PMA exists for Barricaid for skeletally mature patients with radiculopathy and specified annular defect sizes after single‑level L4–S1 discectomy.

inv-03: Allogeneic intradiscal injections

Percutaneous injection of allogeneic cellular/tissue-based products — evidence summary

Allogeneic intradiscal injections evidence summary: Current evidence is insufficient to support percutaneous intradiscal injection of allogeneic cellular/tissue‑based products for discogenic pain; available RCTs and feasibility studies report mixed or non‑definitive outcomes, small sample sizes, loss to follow‑up, and limited independent replication and long‑term data.

Some single‑arm feasibility studies report clinically meaningful improvements (e.g., Costandi 2025), but the randomized VAST/Beall RCT did not demonstrate clear benefit versus placebo for most patient‑oriented outcomes at 12 months; additional robust RCTs and longer‑term outcomes are needed.

inv-04: Thermal intradiscal procedures (IDET, IDB, ID-PRF)

Thermal intradiscal procedures (TIPs) — evidence summary

TIPs evidence summary: Overall there is insufficient high‑quality evidence to support thermal intradiscal procedures broadly for discogenic pain. Systematic review evidence identifies Level I support for biacuplasty based on two RCTs, mixed evidence for IDET (Level III), and limited evidence for other devices/techniques; many positive reports are single‑center, nonrandomized, or small samples with short follow‑up.

Predictors of better outcomes in nonrandomized and cohort studies include high‑grade Dallas discogram scale, presence of a high‑intensity zone (HIZ), certain spinal levels (e.g., L3–L4), preserved disc height, and prior failure of conservative care.

inv-05: Procedure-specific coverage rationale

Coverage stance is based on trial evidence and guideline positions:

Intradiscal biacuplasty (IDB): Randomized trials (Desai et al.) demonstrated statistically and clinically meaningful pain reduction at 6 and 12 months versus conventional medical management in selected single‑level discogenic pain patients; limitations include lack of sham comparator, potential loss to follow‑up, and limited long‑term data.

Helm systematic review rated biacuplasty as Level I evidence based on available RCTs; consider only in patients meeting trial selection criteria and after conservative therapy.

Intradiscal electrothermal therapy (IDET): Evidence is mixed: some RCTs showed benefit while others did not; Helm review rated IDET as Level III (moderate) evidence.

Use may be considered for carefully selected patients matching trial criteria and only after appropriate conservative management.

Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT)/discTRODE: A placebo‑controlled RCT (Kvarstein et al.) did not show benefit of PIRFT (discTRODE) over sham at 6 or 12 months; evidence is insufficient to support routine coverage and some authors advise against intra‑annular discTRODE therapy based on trial findings.

The policy identifies several interventions as unproven and not medically necessary for the treatment of discogenic low back pain: annular closure devices (ACDs), percutaneous injection of allogeneic cellular/tissue-based products, and thermal intradiscal procedures (TIPs). These procedures are listed as excluded from coverage because the current evidence base is insufficient to establish their safety and efficacy for routine treatment of discogenic pain.

Available evidence for percutaneous allogeneic cellular/tissue-based injections is limited and of inadequate quality to support routine clinical use; high-quality randomized trials with larger sample sizes and longer follow-up are needed. Similarly, the body of evidence for thermal intradiscal procedures (TIPs) is insufficient—existing studies are small, heterogeneous, and of limited duration—so these approaches cannot be considered established therapies at this time.

Procedures with inconsistent or limited evidence, such as PIRFT/discTRODE, are explicitly not supported by randomized trial data demonstrating benefit versus sham or control. The Kvarstein RCT of discTRODE found no difference between active and sham treatment at primary endpoints and the study authors did not recommend intra‑annular thermal therapy with that probe; guideline bodies (NICE, NASS) similarly note inconsistent or insufficient efficacy data for these techniques.

Accordingly, the policy considers the listed procedures—including annular closure devices, percutaneous allogeneic intradiscal injections, and thermal intradiscal procedures—as not medically necessary for the management of discogenic low back pain in the absence of stronger, consistent evidence of clinical benefit.

Reiterating the evidence limitations: current trials and reviews do not yet provide robust, reproducible proof of long‑term safety and efficacy for percutaneous allogeneic injections or for the broad category of thermal intradiscal procedures. Until further high‑quality RCTs with adequate sample sizes and follow‑up are available, these interventions remain unsupported for routine coverage.

The Kvarstein et al. randomized, placebo‑controlled trial of intra‑annular PIRFT with the discTRODE probe did not demonstrate superiority over sham treatment at the primary endpoints; the authors reported cases of increased pain and stated they would not recommend the intra‑annular discTRODE thermal therapy given their findings. This specific negative RCT result supports exclusion of discTRODE‑based intra‑annular thermal therapy from routine coverage.

Conservative Care and Trial Requirements

inv-34: Failure of conservative care in many studies' inclusion criteria — typically >6 weeks

Failure of conservative care in many studies' inclusion criteria

Conservative care duration in trials: Most studies of intradiscal interventions enrolled patients who had failed more than six weeks of conservative care or had contraindications to conservative treatment; Hayes assessment explicitly notes failure of >6 weeks as common trial inclusion criteria.more than 6 weeks (as referenced in Hayes assessment)

Documentation of prior conservative care is expected when applying trial‑based criteria.

inv-35: Documented failure of conservative care is expected prior to considering these interventions — typically >6 weeks

Documented failure of conservative care is expected prior to considering these interventions:

Documented failure of conservative care: Most included trials required prior conservative care (commonly >6 weeks or several months) or documented contraindications to conservative management; payers expect documentation of the prior conservative care history before considering intradiscal procedures.

Provider Requirements, Prior Authorization, and Documentation

Note

Applicable procedure codes (reference)

The following list(s) of procedure and diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws. Inclusion of a code does not imply reimbursement or guarantee claim payment. Other policies may apply.

Applicable CPT/HCPCS (reference): 0627T, 0628T, 0629T, 0630T, 22526, 22527, 22899, 63032, S2348
Provider reminder: Inclusion of a code in this policy does not guarantee coverage — verify member benefits and any other applicable policies

Prior Authorization

Prior authorization required (expected)

Prior authorization is expected/required for select intradiscal interventions and device implantations. Providers should obtain prior authorization before scheduling procedures to avoid claim denials.

Prior authorization generally expected for: ACD implantation (e.g., CPT 63032 when billed with annular closure device implantation), percutaneous injection of allogeneic cellular/tissue-based products (CPT 0627T–0630T), and thermal intradiscal procedures (e.g., 22526, 22527, S2348).

Procedure and CPT/HCPCS Codes

Applicable procedure codes listedmixed

0627T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level.
0628T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure)
0629T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level.
0630T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure).
22526	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level.
22527	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure).
22899	Unlisted procedure, spine.
63032	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; with repair of annular defect by implantation of bone-anchored annular closure device, including all imaging guidance, 1 interspace, lumbar (List separately in addition to code for primary procedure)
S2348	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar

Applicable CPT Codes (updated)CPT

63032

Added to applicable CPT codes (document notes annual edits)

Annular defect size (Hayes inclusion)

Typical inclusion thresholdAnnular defects typically defined as ≥ 6 mm width in Hayes assessment and trial inclusion criteria

Clinical contextUsed to identify patients at higher risk of recurrent lumbar disc herniation after discectomy

Associated trial criteriaMost studies enrolled patients who had failed >6 weeks of conservative care or had contraindications to conservative treatment

Imaging and Selection Criteria

Billing Rule

Imaging guidance required (fluoroscopy or CT) per procedure code

Fluoroscopy or CT guidance is required as specified by the procedure code for IDET, IDB, PIRFT, and percutaneous allogeneic intradiscal injections.

0627T/0628T specify fluoroscopic guidance; 0629T/0630T specify CT guidance.
TIPs are performed under fluoroscopic guidance per procedure descriptions.

Documentation Required

Use MRI and discography findings for IDET/IDB and ACD candidacy selection

Selection criteria for IDET/IDB and ACD candidacy should document relevant MRI and, when used in trials, discography findings and morphologic characteristics that matched study inclusion criteria.

Key Definitions

Definition — Annular closure device (ACD)

TermAnnular closure device (ACD)

DefinitionDevice designed to reinforce or bridge the annulus fibrosus defect after discectomy to close the defect and repair the annulus fibrosus

PurposeIntended to prevent recurrent lumbar disc herniation by closing annular defects

Definition — Thermal intradiscal procedures (TIPs)

TermThermal intradiscal procedures (TIPs)

DefinitionPercutaneous procedures inserting a catheter or probe into the disc under fluoroscopic guidance to apply heat within the disc to relieve low back pain; includes IDET, IDB/biacuplasty, and PIRFT

Frequency and Reoperation Reporting

ACD implantation and related reoperation reporting — frequency

Frequency limits specifiedNot specified in policy for ACD implantation or related reoperation reporting

DocumentationStudies report follow-up intervals (6 weeks, 3 months, 6 months, annually) but the policy does not set procedural frequency limits

ImplicationPrior authorization should reference clinical trial reporting but frequency caps are not provided in this document portion

Frequency limits — intradiscal thermal procedures

Frequency limits specifiedNot specified for intradiscal thermal procedures in this portion of the document

Evidence reportingRandomized trials and systematic reviews cited, but no policy-level frequency limits or repeat procedure intervals are defined here

Non-Covered Services

Not covered under this policy are the following procedures for treating discogenic low back pain: annular closure devices (ACDs), percutaneous injection of allogeneic cellular/tissue-based products, and thermal intradiscal procedures (TIPs). These are considered investigational or not medically necessary due to insufficient evidence of efficacy.

This policy similarly designates the following as not covered: annular closure devices, percutaneous allogeneic intradiscal injections, and thermal intradiscal procedures, reflecting the consistent stance that current evidence does not establish their effectiveness for routine care.

As restated elsewhere in the document, the procedures listed above—including ACD implantation, percutaneous allogeneic cellular/tissue injections, and TIPs—are categorized as not covered/investigational because of inadequate high‑quality evidence demonstrating net clinical benefit.

In particular, percutaneous allogeneic intradiscal injections and thermal intradiscal procedures are identified as having insufficient evidence to support clinical use. The discTRODE PIRFT RCT is an example of a randomized study that failed to show benefit versus sham and raised safety concerns, reinforcing the policy position that these techniques are not supported for routine coverage.

Additional entries in the not‑covered list reiterate that annular closure devices, percutaneous allogeneic cellular/tissue‑based disc injections, and thermal intradiscal procedures are considered investigational or not medically necessary pending more robust evidence.

Background and Scope

Discogenic low back pain arises from degeneration or internal disruption of the intervertebral disc and may present as axial low back pain with or without radicular symptoms. Interventions discussed in this policy include devices intended to repair or close annular defects after discectomy (annular closure devices), percutaneous thermal intradiscal procedures that apply heat to alter nociceptors or disc tissue (examples: IDET, intradiscal biacuplasty, PIRFT), and percutaneous injections of allogeneic cellular or tissue products intended to stimulate disc repair. These procedures are minimally invasive and typically performed under imaging guidance.

OpenPayer

Discogenic Pain Treatment